US20090169657A1 - Phaseolus vulgaris extracts, their use, and formulations containing them - Google Patents
Phaseolus vulgaris extracts, their use, and formulations containing them Download PDFInfo
- Publication number
- US20090169657A1 US20090169657A1 US12/158,063 US15806306A US2009169657A1 US 20090169657 A1 US20090169657 A1 US 20090169657A1 US 15806306 A US15806306 A US 15806306A US 2009169657 A1 US2009169657 A1 US 2009169657A1
- Authority
- US
- United States
- Prior art keywords
- extract
- ethanol
- extracts
- extraction
- precipitation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to extracts obtained from the seeds of plants of the genus Phaseolus , and the process for the preparation thereof.
- this invention relates to extracts of Phaseolus vulgaris seeds, characterised by a content in ⁇ -amylase inhibitors and phytohaemagglutinins in established ratios which reduce the absorption of glucose originating from starches in the diet, and reduce the appetite after repeated administration.
- ⁇ -Amylase inhibitor is a glycoprotein contained in the seeds of kidney beans ( Phaseolus vulgaris ) which inhibits the enzymatic activity of amylase of animal origin, and especially human amylase, in a differentiated, species-dependent way.
- This inhibitor which was purified for the first time by Marshall and Lauda in 1974 (J. Biol. Chem., 250 (20), 8030-8037, 1975), has attracted interest because of the effects which its pancreatic amylase inhibiting activity can exert on the intestinal absorption of glucose (deriving from enzymatic hydrolysis of starch), and above all for its potential application in the diet industry.
- Carbohydrates are an important source of calories and contribute to the synthesis of fats in individuals that are predisposed to obesity or Type II diabetes.
- the availability of food for survival was intermittent, so the ability to accumulate energy in excess of the amount required for immediate use was essential.
- the adipose cells developed in different parts of the body, are among the sites where energy is accumulated, so that it is easily available when the body needs it. This physiological system, orchestrated by endocrine and neurone secretions, enables humans to survive for long periods, even in the absence of food.
- ⁇ -Amylase inhibitors have long been identified in different legumes and corn, and specific clinical trials have been conducted in last years, with mixed results. Depending on the preparation process used for the concentration and isolation of these inhibitors, the results have been contradictory, as many commercial preparations proved to lack effective activity in vivo. According to the first studies of Layer, Carlson and Di Magno (Gastroenterology, 88(6): 1895, 1902, 1985), this problem is apparently due to the high degree of dilution of the inhibitor in highly impure preparations; in fact, preparations of purified inhibitor are proved to be active on ⁇ -amylase when are directly introduced into the intestinal lumen.
- the products according to the invention are prepared by extraction with an aqueous or hydroethanolic medium and precipitation with suitable mixtures of ethanol and water.
- the process of the invention comprises extraction of the biomass with buffers having a pH ranging between 3 and 6.5, preferably pH 3.5-5.5, and even more preferably pH 4, at temperatures of between 2 and 25° C., and preferably between 4 and 18° C., and subsequent separation of the extract from the biomass by centrifugation.
- buffers having a pH ranging between 3 and 6.5, preferably pH 3.5-5.5, and even more preferably pH 4, at temperatures of between 2 and 25° C., and preferably between 4 and 18° C.
- Suitable buffers for the extraction are typically phosphate, citrate or acetate buffers or dicarboxylic aminoacid buffers, preferably phosphate or citrate buffer. Buffered water-alcohol mixtures can also be used as extraction solvent.
- the biomass can be further extracted three more times with a suitable quantity of buffer, and in any case until its ⁇ -amylase inhibitor and phytohaemagglutinin content is exhausted.
- the combined extracts are clarified by filtration or centrifugation and concentrated in vacuum at a temperature of between 25° and 35° C., preferably 30° C., or by ultrafiltration (10,000 Da cut-off) to a volume corresponding to approx. 10% of the weight of the extract after centrifugation.
- the concentrated aqueous extract is then precipitated with ethanol added to a final concentration of between 60 and 70% v/v, preferably 65% v/v, operating at a temperature of between 18° and 30° C., and preferably between 20° and 25° C.
- the obtained precipitate can be centrifuged and/or filtered, redissolved in demineralised water and re-precipitated in 60% ethanol to reduce the saline part. Alternatively, it can be diafiltered through a membrane with a 10,000 Da cut-off.
- the sediment of the precipitation, which constitutes the extract according to the invention, is dried.
- the efficacy of the extracts has been proved in rats treated with doses of 200 and 400 mg/Kg a day, with free access to the food consisting of a special starch-enriched diet.
- the extracts according to the invention reduce food consumption significantly, while water consumption remains unchanged.
- the product according to the invention is perfectly tolerated, and can be incorporated into pharmaceutical or diet formulations at doses ranging between 50 and 1.000 mg, to be taken at main meals.
- the extract can be incorporated in drinkable forms or the like, to be taken as appetite suppressants.
- the suspension was centrifuged, and the aqueous centrifugate was concentrated 7.5 times (dry residue: 15.0% w/w).
- the concentrate was diluted with 95% ethanol to a concentration of 65% ethanol to obtain a precipitate which was recovered by centrifugation at +22° C.
- the collected solid was dried under vacuum at a temperature not exceeding 50° C.
- the obtained product (yield 2.36%) has an ⁇ -amylase inhibiting activity of 1.050 U/mg, a haemagglutinating activity of 9,000 HAU/g, and an HPLC titre of 7.3% w/w.
- the suspension was centrifuged, and the aqueous centrifugate was concentrated 10.5 times (dry residue: 17.1% w/w).
- the concentrate was diluted with 95% ethanol to a concentration of 65% ethanol to obtain a precipitate which was recovered by centrifugation at +22° C.
- the collected solid was dried under vacuum at a temperature not exceeding 50° C.
- the obtained product (yield 3.5%) has an ⁇ -amylase inhibiting activity of 1,600 U/mg, a haemagglutinating activity of 18,600 HAU/g and an HPLC titre of 10.0% w/w.
- the suspension was centrifuged, the clear liquid phase discarded, and the sediment subjected to a new extraction cycle with 750 mL of water.
- the liquid phase of the second extraction was combined with the first, and concentrated 4.3 times (dry residue: 4.78% w/w).
- the concentrate was diluted with 95% ethanol to a concentration of 70% ethanol to obtain a precipitate which was recovered by centrifugation at +22° C.
- the collected solid was dried under vacuum at a temperature not exceeding 50° C.
- the obtained product (yield 0.88%) has an ⁇ -amylase inhibiting activity of 1,570 U/mg, a haemagglutinating activity of 27,000 HAU/g, and an HPLC titre of 13.6% w/w.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Extraction Or Liquid Replacement (AREA)
- Peptides Or Proteins (AREA)
Abstract
Extract obtainable by extraction from Phaseolus sp. with mixtures of ethanol and water, characterised by an α-amylase inhibitor content in between 1,000 and 1,600 USP/mg (HPLC titre between 6 and 14% w/w) and a phytohaemagglutinin content in between 8,000 and 30,000 HAU/g, and a process for its preparation.
Description
- This invention relates to extracts obtained from the seeds of plants of the genus Phaseolus, and the process for the preparation thereof.
- More particularly, this invention relates to extracts of Phaseolus vulgaris seeds, characterised by a content in α-amylase inhibitors and phytohaemagglutinins in established ratios which reduce the absorption of glucose originating from starches in the diet, and reduce the appetite after repeated administration.
- α-Amylase inhibitor (αAI) is a glycoprotein contained in the seeds of kidney beans (Phaseolus vulgaris) which inhibits the enzymatic activity of amylase of animal origin, and especially human amylase, in a differentiated, species-dependent way. This inhibitor, which was purified for the first time by Marshall and Lauda in 1974 (J. Biol. Chem., 250 (20), 8030-8037, 1975), has attracted interest because of the effects which its pancreatic amylase inhibiting activity can exert on the intestinal absorption of glucose (deriving from enzymatic hydrolysis of starch), and above all for its potential application in the diet industry. Carbohydrates are an important source of calories and contribute to the synthesis of fats in individuals that are predisposed to obesity or Type II diabetes. In nature, in the evolution of the species, the availability of food for survival was intermittent, so the ability to accumulate energy in excess of the amount required for immediate use was essential. The adipose cells, developed in different parts of the body, are among the sites where energy is accumulated, so that it is easily available when the body needs it. This physiological system, orchestrated by endocrine and neurone secretions, enables humans to survive for long periods, even in the absence of food. However, in the event of abundant food, sedentary lifestyle and genetic reasons associated with the lifestyles of industrialised countries, the system increases uncontrollably the adipose energy deposits with adverse consequences, such as beauty flaw, followed by an overload of the cardiocirculatory system. One of the main problems is obesity, which has reached high levels in some countries, such as the United States of America. Obesity is the primary cause of cardiovascular disease, hypertension and diabetes. Excess weight, which is common among both men and women, causes the subject to eat larger and larger amounts of food, and the result is a deterioration in health. As excess blood glucose leads to an increase in energy deposits, the availability of substances that reduce glucose absorption is very important.
- Worldwide demand for anti-obesity substances has led to research and study of foods that counteract the progressive body weight accumulation.
- α-Amylase inhibitors have long been identified in different legumes and corn, and specific clinical trials have been conducted in last years, with mixed results. Depending on the preparation process used for the concentration and isolation of these inhibitors, the results have been contradictory, as many commercial preparations proved to lack effective activity in vivo. According to the first studies of Layer, Carlson and Di Magno (Gastroenterology, 88(6): 1895, 1902, 1985), this problem is apparently due to the high degree of dilution of the inhibitor in highly impure preparations; in fact, preparations of purified inhibitor are proved to be active on α-amylase when are directly introduced into the intestinal lumen.
- The fragmentary processes described in the literature for the preparation of α-amylase inhibitors involve the extraction with phosphate buffer and the insolubilisation of proteins with ammonium sulphate, and do not provide any selectivity. The obtained extracts contain high concentrations of phytohaemagglutinins, and must be diluted to obtain extracts with an acceptable level of toxicity. Apart from the biological aspect, known processes include some stages which make difficult to prepare a product that is both active and safe. The problems that arise during extraction with buffers of different ionic strengths and pH are due to the high concentration of protein and polysaccharide contaminants, which make them highly viscous, leading to problems of low filterability and longer processing times. As these are aqueous extractions, there is also a high risk of microbial contamination of the protein extract, which is difficult to control, especially in the case of highly viscous preparations. All these conditions lead to a loss of product and make difficult to obtain final extracts with a low phytohaemagglutinin titre and the corresponding multicomponent standardisation. Various processes have been used to solve the problem of limiting phytohaemagglutinins, including heat treatments, which lead to the breakdown not only of phytohaemagglutinins, but also of α-amylase inhibitors, with the result that the obtained products are scarcely active. In practice, the products on the market have a very low αAI content. Other products which are too highly enriched in α-amylase inhibitors cause unpleasant problems of flatulence when administered in large doses.
- The products according to the invention are prepared by extraction with an aqueous or hydroethanolic medium and precipitation with suitable mixtures of ethanol and water.
- It has surprisingly been found that the use of hydroethanolic mixtures on suitably concentrated aqueous extracts of kidney bean produces enriched extracts with an α-amylase inhibitor content having an activity of between 1,000 and 1,600 USP/mg (HPLC titre of between 6 and 14% w/w) and a phytohaemagglutinin content in between 8,000 and 30,000 HAU/g, so that it can be formulated in products for diet use at sufficiently low doses to obtain the desired result. In addition to this major advantage, the process to which the invention relates produces a significant reduction in the microbe count. Another considerable advantage is the possibility of obtaining an end product enriched in (αAI) inhibitor, with defined phytohaemagglutinin ratios.
- The process of the invention comprises extraction of the biomass with buffers having a pH ranging between 3 and 6.5, preferably pH 3.5-5.5, and even more preferably pH 4, at temperatures of between 2 and 25° C., and preferably between 4 and 18° C., and subsequent separation of the extract from the biomass by centrifugation.
- Suitable buffers for the extraction are typically phosphate, citrate or acetate buffers or dicarboxylic aminoacid buffers, preferably phosphate or citrate buffer. Buffered water-alcohol mixtures can also be used as extraction solvent.
- Depending on the used extractors and on the extraction cycle, 5 to 20 volumes of buffer per part of drug are used, preferably 10-12.5 parts, and the mixture is stirred for 1-4 hours, preferably 2 hours; the biomass can be further extracted three more times with a suitable quantity of buffer, and in any case until its α-amylase inhibitor and phytohaemagglutinin content is exhausted.
- The combined extracts are clarified by filtration or centrifugation and concentrated in vacuum at a temperature of between 25° and 35° C., preferably 30° C., or by ultrafiltration (10,000 Da cut-off) to a volume corresponding to approx. 10% of the weight of the extract after centrifugation.
- The concentrated aqueous extract is then precipitated with ethanol added to a final concentration of between 60 and 70% v/v, preferably 65% v/v, operating at a temperature of between 18° and 30° C., and preferably between 20° and 25° C.
- The obtained precipitate can be centrifuged and/or filtered, redissolved in demineralised water and re-precipitated in 60% ethanol to reduce the saline part. Alternatively, it can be diafiltered through a membrane with a 10,000 Da cut-off. The sediment of the precipitation, which constitutes the extract according to the invention, is dried.
- If these processes are used, an extract with the following characteristics can be obtained:
-
- HPLC titre: ≧6% ≦14% w/w
- α-amylase inhibiting activity: ≧1,000 ≦1,600 USP/mg
- haemagglutinating activity: ≧8,000 ≦30,000 HAU/g
- The efficacy of the extracts has been proved in rats treated with doses of 200 and 400 mg/Kg a day, with free access to the food consisting of a special starch-enriched diet. During the treatment the extracts according to the invention reduce food consumption significantly, while water consumption remains unchanged.
- The product according to the invention is perfectly tolerated, and can be incorporated into pharmaceutical or diet formulations at doses ranging between 50 and 1.000 mg, to be taken at main meals. The extract can be incorporated in drinkable forms or the like, to be taken as appetite suppressants.
- The examples below set out illustrate the preparation and the advantages of the invention.
- A suspension of 150 g of kidney bean flour in 1.5 L of citric acid 5.75 g/L was stirred for 3 hours at +4° C.
- The suspension was centrifuged, and the aqueous centrifugate was concentrated 7.5 times (dry residue: 15.0% w/w). The concentrate was diluted with 95% ethanol to a concentration of 65% ethanol to obtain a precipitate which was recovered by centrifugation at +22° C. The collected solid was dried under vacuum at a temperature not exceeding 50° C. The obtained product (yield 2.36%) has an α-amylase inhibiting activity of 1.050 U/mg, a haemagglutinating activity of 9,000 HAU/g, and an HPLC titre of 7.3% w/w.
- A suspension of 150 g of kidney bean flour in 1.5 L of citric acid 5.75 g/L was stirred for 2 hours at +22° C.
- The suspension was centrifuged, and the aqueous centrifugate was concentrated 10.5 times (dry residue: 17.1% w/w). The concentrate was diluted with 95% ethanol to a concentration of 65% ethanol to obtain a precipitate which was recovered by centrifugation at +22° C. The collected solid was dried under vacuum at a temperature not exceeding 50° C. The obtained product (yield 3.5%) has an α-amylase inhibiting activity of 1,600 U/mg, a haemagglutinating activity of 18,600 HAU/g and an HPLC titre of 10.0% w/w.
- A suspension of 100 g of kidney bean flour in 1.0 L of a 70:30 mixture of water and ethanol, containing citric acid 4.6 g/L, was stirred for 2 hours at +22° C.
- The suspension was centrifuged, the clear liquid phase discarded, and the sediment subjected to a new extraction cycle with 750 mL of water. The liquid phase of the second extraction was combined with the first, and concentrated 4.3 times (dry residue: 4.78% w/w). The concentrate was diluted with 95% ethanol to a concentration of 70% ethanol to obtain a precipitate which was recovered by centrifugation at +22° C. The collected solid was dried under vacuum at a temperature not exceeding 50° C. The obtained product (yield 0.88%) has an α-amylase inhibiting activity of 1,570 U/mg, a haemagglutinating activity of 27,000 HAU/g, and an HPLC titre of 13.6% w/w.
Claims (5)
1. Extract obtainable by extraction from Phaseolus sp. with mixtures of ethanol and water, characterised by an α-amylase inhibitor content in between 1,000 and 1,600 USP/mg (HPLC titre between 6 and 14% w/w) and a phytohaemagglutinin content in between 8,000 and 30,000 HAU/g.
2. Process for the preparation of the extract claimed in claim 1 , which comprises:
a) Extraction of Phaseolus sp. with aqueous buffers having a pH ranging between 3 and 6.5, and subsequent separation of the extract from the biomass, which can be further extracted with the buffer if required until the α-amylase inhibitors and phytohaemagglutinins are exhausted;
b) Filtration or centrifugation of the combined extracts, and concentration to a volume corresponding to approx. 10% of the weight of the extract after centrifugation;
c) Differential precipitation of the concentrated aqueous extract with diluted ethanol, at a final alcohol concentration of between 60 and 70% v/v;
d) Separation of precipitate and re-precipitation from demineralised water with 60% ethanol, or diafiltration through a membrane with a 10,000 Da cut-off, and drying of precipitation residue.
3. Process as claimed in claim 2 , wherein phosphate, citrate or acetate buffers, dicarboxylic aminoacid buffers, or buffered water-alcohol solutions are used.
4. Use of the extracts claimed in claim 1 to prepare appetite suppressants.
5. Compositions containing the extracts claimed in claim 1 .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002450A ITMI20052450A1 (en) | 2005-12-22 | 2005-12-22 | PHASEOLUS VULGARIS EXTRACTS THEIR USE AND FORMULATIONS THAT CONTAIN THEM |
ITMI2005A002450 | 2005-12-22 | ||
PCT/EP2006/012012 WO2007071334A2 (en) | 2005-12-22 | 2006-12-13 | Ethanol-precipitated phaseolus vulgaris extracts, their use and formulations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/012012 A-371-Of-International WO2007071334A2 (en) | 2005-12-22 | 2006-12-13 | Ethanol-precipitated phaseolus vulgaris extracts, their use and formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/643,900 Division US11241470B2 (en) | 2005-12-22 | 2017-07-07 | Phaseolus vulgaris extracts, their use and formulations containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090169657A1 true US20090169657A1 (en) | 2009-07-02 |
Family
ID=37888415
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/158,063 Abandoned US20090169657A1 (en) | 2005-12-22 | 2006-12-13 | Phaseolus vulgaris extracts, their use, and formulations containing them |
US15/643,900 Active 2028-07-28 US11241470B2 (en) | 2005-12-22 | 2017-07-07 | Phaseolus vulgaris extracts, their use and formulations containing them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/643,900 Active 2028-07-28 US11241470B2 (en) | 2005-12-22 | 2017-07-07 | Phaseolus vulgaris extracts, their use and formulations containing them |
Country Status (18)
Country | Link |
---|---|
US (2) | US20090169657A1 (en) |
EP (1) | EP1962877B1 (en) |
JP (1) | JP5452931B2 (en) |
KR (1) | KR101449763B1 (en) |
CN (1) | CN101340923B (en) |
AU (1) | AU2006328983B2 (en) |
BR (1) | BRPI0620054A8 (en) |
CA (1) | CA2634345C (en) |
DK (1) | DK1962877T3 (en) |
ES (1) | ES2813929T3 (en) |
HK (1) | HK1127995A1 (en) |
IL (1) | IL192292A (en) |
IT (1) | ITMI20052450A1 (en) |
NO (1) | NO346419B1 (en) |
PT (1) | PT1962877T (en) |
RU (1) | RU2426552C2 (en) |
SI (1) | SI1962877T1 (en) |
WO (1) | WO2007071334A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014165030A2 (en) | 2013-03-13 | 2014-10-09 | Sunny Delight Beverages Company | Process for enhancing the amylase inhibitory efficacy from phaseolus vulgaris extracts |
US20150258157A1 (en) * | 2012-10-12 | 2015-09-17 | Indena S.P.A. | Formulations for the treatment and prevention of obesity |
CN116270793A (en) * | 2023-02-07 | 2023-06-23 | 湖南朗林生物资源股份有限公司 | Preparation method and application of white kidney bean extract |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1967198T1 (en) | 2007-03-07 | 2009-08-31 | Indena Spa | Formulations containing cynara scolymus and phaseolus vulgaris extracts which are useful in the treatment of obesity |
CN101555275B (en) * | 2009-05-08 | 2011-09-28 | 广东省食品工业研究所 | Method for preparing alpha-amylase inhibitor by enzymatic method |
KR20110138001A (en) * | 2010-06-18 | 2011-12-26 | (주)아모레퍼시픽 | Composition comprising colored-bean extracts |
TW201427674A (en) * | 2013-01-15 | 2014-07-16 | ji-min Song | Phaseolus vulgaris seed extract and its preparation method and uses |
UA118980C2 (en) * | 2015-01-14 | 2019-04-10 | Акоп Сурікович Куцанян | Method for producing a complex of biologically active substances exhibiting hypoglycemic activity |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7553502B2 (en) * | 2007-03-07 | 2009-06-30 | Indena S.P.A. | Formulations of alpha-amylase inhibitors with alpha-glucosidase inhibitors useful in the treatment of diabetes and obesity |
US7887854B2 (en) * | 2007-03-07 | 2011-02-15 | Indena S.P.A. | Formulations containing Cynara scolymus and Phaseolus vulgaris extracts which are useful in the treatment of obesity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2628757A1 (en) * | 1976-06-26 | 1977-12-29 | Guenter Dr Woeber | Amylase inhibitor from Phaseolus vulgaris - active against amylase from saliva or pancreas, does not inhibit alpha-amylase from e.g. Bacillus subtilis |
JPH06116197A (en) | 1992-09-07 | 1994-04-26 | Max Fuakutaa Kk | New radical scavenger |
US6797287B2 (en) * | 2001-09-25 | 2004-09-28 | Pharmachem Laboratories, Inc. | Phaseolamin compositions and methods for using the same |
US20060147565A1 (en) * | 2002-06-28 | 2006-07-06 | Pharmachem Laboratories, Inc. | Purified amylase inhibitor and novel process for obtaining the same |
US20040131749A1 (en) * | 2002-08-29 | 2004-07-08 | Archer-Daniels-Midland Company | Phytochemicals from edible bean process streams |
ITMI20040619A1 (en) * | 2004-03-30 | 2004-06-30 | Consiglio Nazionale Ricerche | PURIFIED EXTRACT OF ALFA-AMYLASE INHIBITOR FROM BEANS ESSENTIALLY FREE OF PHYTOHEMAGGLUTININ EXTRACTION PROCEDURE AND COMPOSITIONS CONTAINING IT |
-
2005
- 2005-12-22 IT IT002450A patent/ITMI20052450A1/en unknown
-
2006
- 2006-12-13 CA CA2634345A patent/CA2634345C/en active Active
- 2006-12-13 WO PCT/EP2006/012012 patent/WO2007071334A2/en active Application Filing
- 2006-12-13 EP EP06829580.7A patent/EP1962877B1/en active Active
- 2006-12-13 JP JP2008546204A patent/JP5452931B2/en active Active
- 2006-12-13 ES ES06829580T patent/ES2813929T3/en active Active
- 2006-12-13 CN CN2006800480680A patent/CN101340923B/en active Active
- 2006-12-13 KR KR1020087014705A patent/KR101449763B1/en active IP Right Grant
- 2006-12-13 US US12/158,063 patent/US20090169657A1/en not_active Abandoned
- 2006-12-13 AU AU2006328983A patent/AU2006328983B2/en active Active
- 2006-12-13 DK DK06829580.7T patent/DK1962877T3/en active
- 2006-12-13 BR BRPI0620054A patent/BRPI0620054A8/en not_active Application Discontinuation
- 2006-12-13 PT PT68295807T patent/PT1962877T/en unknown
- 2006-12-13 RU RU2008124974/15A patent/RU2426552C2/en active
- 2006-12-13 SI SI200632384T patent/SI1962877T1/en unknown
-
2008
- 2008-06-19 IL IL192292A patent/IL192292A/en active IP Right Grant
- 2008-06-19 NO NO20082729A patent/NO346419B1/en unknown
-
2009
- 2009-06-19 HK HK09105551.1A patent/HK1127995A1/en unknown
-
2017
- 2017-07-07 US US15/643,900 patent/US11241470B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7553502B2 (en) * | 2007-03-07 | 2009-06-30 | Indena S.P.A. | Formulations of alpha-amylase inhibitors with alpha-glucosidase inhibitors useful in the treatment of diabetes and obesity |
US7887854B2 (en) * | 2007-03-07 | 2011-02-15 | Indena S.P.A. | Formulations containing Cynara scolymus and Phaseolus vulgaris extracts which are useful in the treatment of obesity |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150258157A1 (en) * | 2012-10-12 | 2015-09-17 | Indena S.P.A. | Formulations for the treatment and prevention of obesity |
US9901610B2 (en) * | 2012-10-12 | 2018-02-27 | Indena S.P.A. | Formulations for the treatment and prevention of obesity |
US10967033B2 (en) | 2012-10-12 | 2021-04-06 | Indena S.P.A. | Formulations for the treatment and prevention of obesity |
WO2014165030A2 (en) | 2013-03-13 | 2014-10-09 | Sunny Delight Beverages Company | Process for enhancing the amylase inhibitory efficacy from phaseolus vulgaris extracts |
US9290752B2 (en) | 2013-03-13 | 2016-03-22 | Sunny Delight Beverages Co. | Process for enhancing the amylase inhibitory efficacy from phaseolus vulgaris extracts |
CN116270793A (en) * | 2023-02-07 | 2023-06-23 | 湖南朗林生物资源股份有限公司 | Preparation method and application of white kidney bean extract |
Also Published As
Publication number | Publication date |
---|---|
NO346419B1 (en) | 2022-07-18 |
AU2006328983A1 (en) | 2007-06-28 |
WO2007071334A2 (en) | 2007-06-28 |
NO20082729L (en) | 2008-07-08 |
CN101340923A (en) | 2009-01-07 |
ITMI20052450A1 (en) | 2007-06-23 |
ES2813929T3 (en) | 2021-03-25 |
RU2008124974A (en) | 2009-12-27 |
BRPI0620054A2 (en) | 2011-11-01 |
CA2634345A1 (en) | 2007-06-28 |
PT1962877T (en) | 2020-09-04 |
HK1127995A1 (en) | 2009-10-16 |
RU2426552C2 (en) | 2011-08-20 |
WO2007071334A3 (en) | 2007-09-13 |
US20170333508A1 (en) | 2017-11-23 |
DK1962877T3 (en) | 2020-08-31 |
US11241470B2 (en) | 2022-02-08 |
CA2634345C (en) | 2016-09-27 |
KR20080080127A (en) | 2008-09-02 |
IL192292A (en) | 2013-05-30 |
CN101340923B (en) | 2013-11-06 |
AU2006328983B2 (en) | 2012-06-28 |
KR101449763B1 (en) | 2014-10-13 |
EP1962877B1 (en) | 2020-07-22 |
IL192292A0 (en) | 2008-12-29 |
BRPI0620054A8 (en) | 2018-12-26 |
JP2009520716A (en) | 2009-05-28 |
EP1962877A2 (en) | 2008-09-03 |
SI1962877T1 (en) | 2020-09-30 |
JP5452931B2 (en) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11241470B2 (en) | Phaseolus vulgaris extracts, their use and formulations containing them | |
CN101257914B (en) | Composition for amelioration of body lipid | |
WO2013100105A1 (en) | Maillard reaction inhibitor | |
WO2019203136A1 (en) | Food composition for improving cognitive function, cognitive function improvement agent, and production method thereof | |
JP2009137929A (en) | Method for producing polyphenol extract, prophylactic agent for osteoporosis, saccharide-digesting enzyme inhibitor, functional compositions using them, and food composition, food composition for specified health use, quasi-drug composition, and pharmaceutical composition each containing the functional composition | |
JP2006241023A (en) | Agent for inducing expression or accelerating production of antibacterial peptide in digestive tract tissue | |
JP2001002583A (en) | Blood sugar level increase inhibitor | |
JP4673071B2 (en) | Iron-adsorptive polymer substance, iron-containing polymer substance, and production method thereof | |
JP2006273762A (en) | Uricosuric agent | |
US20090093397A1 (en) | Phaseolus vulgaris extracts, their use, and formulations containing them | |
JP2006016340A (en) | Blood uric acid level reduction agent having extract of punica granatum l. as active ingredient | |
JP2011036241A (en) | Method for preparation of angiotensin-converting enzyme inhibitor peptide | |
JP3522373B2 (en) | Lactic acid bacteria growth promoter | |
KR20060106065A (en) | Hepato-protective effects of angelica keiskei root extract, 4-hydroxyderricin and xanthoangelol | |
JP2001299272A (en) | Lipase inhibitor | |
KR20200016610A (en) | Composition for Improvement of Fatty Liver | |
JPH08157385A (en) | Bowl movement improver, agent for enhancing prolifration of gut mucosa and perpectal nutrition promoting agent | |
TW202200179A (en) | Composition for inhibiting phosphodiesterase 5 activity or improving erectile function by using a plant of the genus Phyllanthus | |
RU2218030C2 (en) | Method of preparing biologically active additive "erosil" from genitals of reindeer, biologically active additive "erosil", method of preparing complex biologically active additive "penisil", and complex biologically active additive "penisil" | |
KR20100121351A (en) | Phaseolus vulgaris extracts, their use, and formulations containing them | |
JP2019030229A (en) | Aspergillus oryzae, enzyme derived from aspergillus oryzae, blood glucose level rise inhibitor, food and beverage, pharmaceutical composition, food additive, supplement and manufacturing methods for the same, blood glucose level rise inhibiting method, and sugar uptake promotion method | |
JP2020083824A (en) | Mucin production promoter | |
JP2006137712A (en) | Antitumor agent and food and drink | |
JPH078214A (en) | Oral medicine and beverage having appetite-increasing action | |
JP2000297042A (en) | Active oxygen scavenger |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INDENA S.P.A., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BERLANDA, DAVIDE;BERTANI, MARCO;BOMBARDELLI, EZIO;AND OTHERS;REEL/FRAME:021249/0734 Effective date: 20080708 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |